Search results for "Clinical Decision-Making"

showing 10 items of 56 documents

Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and C…

2022

Abstract Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored the added benefits of serial analysis: assessing adjuvant chemotherapy (ACT) efficacy, early relapse detection, and ctDNA growth rates. Experimental Design: We recruited 168 patients with stage III colorectal cancer treated with curative intent at Danish and Spanish hospitals between 2014 and 2019. To quantify ctDNA in plasma samples (n = 1,204), 16 patient-specific somatic sing…

MaleOncologyCancer Researchmedicine.medical_specialtyNeoplasm ResidualAdjuvant chemotherapyClinical Decision-MakingCirculating Tumor DNAText miningPredictive Value of TestsInternal medicineBiomarkers TumorStage III colorectal cancermedicineAdjuvant therapyHumansTumor growthAgedNeoplasm Stagingbusiness.industryPrognosisMinimal residual diseaseConfidence intervalOncologyCirculating tumor DNAFemaleDrug MonitoringNeoplasm Recurrence LocalColorectal NeoplasmsbusinessClinical Cancer Research
researchProduct

Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study

2018

Prognostic assessment of patients with hepatocellular carcinoma (HCC) at the time of diagnosis remains controversial and becomes even more complex at the time of restaging when new variables need to be considered. The aim of the current study was to evaluate the prognostic utility of restaging patients before proceeding with additional therapies for HCC. Two independent Italian prospective databases were used to identify 1,196 (training cohort) and 648 (validation cohort) consecutive patients with HCC treated over the same study period (2008-2015) who had complete restaging before decisions about additional therapies. The performance of the Italian Liver Cancer (ITA.LI.CA) prognostic score …

MaleOncologyDatabases FactualLiver cancer; non surgical therapy; prognostic system; surgical therapy; survivalhepatocellular carcinoma stage treatmentKaplan-Meier EstimateCohort StudiesLiver disease0302 clinical medicineMiddle AgedSorafenibPrognosisItaly030220 oncology & carcinogenesisCatheter AblationDisease ProgressionFemale030211 gastroenterology & hepatologysurgical therapyLiver cancerLiver cancermedicine.drugCohort studySorafenibmedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIAClinical Decision-MakingRisk AssessmentsurvivalDisease-Free SurvivalStatistics Nonparametric03 medical and health sciencesnon surgical therapyInternal medicinemedicineHepatectomyHumansInfusions Intra-ArterialNeoplasm InvasivenessSurvival analysisAgedNeoplasm StagingRetrospective StudiesAnalysis of VarianceHepatologybusiness.industryprognostic systemReproducibility of ResultsCancerRetrospective cohort studymedicine.diseaseSurvival AnalysisbusinessProgressive disease
researchProduct

Non-readmission decisions in the intensive care unit: A qualitative study of physicians' experience in a multicentre French study.

2021

Purpose Deciding not to re-admit a patient to the intensive care unit (ICU) poses an ethical dilemma for ICU physicians. We aimed to describe and understand the attitudes and perceptions of ICU physicians regarding non-readmission of patients to the ICU. Materials and methods Multicenter, qualitative study using semi-directed interviews between January and May 2019. All medical staff working full-time in the ICU of five participating centres (two academic and three general, non-academic hospitals) were invited to participate. Participants were asked to describe how they experienced non-readmission decisions in the ICU, and to expand on the manner in which the decision was made, but also on…

MalePalliative careMedical staffHealth Care ProvidersSocial SciencesNurseslaw.inventionCognition0302 clinical medicinelawSurveys and QuestionnairesMedicine and Health SciencesPsychologyMedicineMedical Personnel030212 general & internal medicineQualitative ResearchMultidisciplinaryPalliative CareQRMiddle AgedQualitative StudiesIntensive care unitHospitalsIntensive Care UnitsProfessionsResearch DesignMedicineFemaleFranceResearch ArticleAdultmedicine.medical_specialtyScienceClinical Decision-MakingDecision MakingMEDLINEResearch and Analysis Methods03 medical and health sciencesQuality of life (healthcare)PhysiciansHumansbusiness.industryCognitive PsychologyBiology and Life SciencesHealth Care030228 respiratory systemHealth Care FacilitiesContent analysisFamily medicinePeople and PlacesEthical dilemmaQuality of LifeCognitive SciencePopulation GroupingsbusinessNeuroscienceQualitative researchPLoS ONE
researchProduct

Clinical Evaluation Versus Undetectable High-Sensitivity Troponin for Assessment of Patients With Acute Chest Pain.

2016

Decision-making in acute chest pain remains challenging despite normal (below ninety-ninth percentile) high-sensitivity troponin (hs-cTn). Some studies suggest that undetectable hs-cTn, far below the ninety-ninth percentile, might rule out acute coronary syndrome. We investigated clinical data in comparison to undetectable hs-cTnT. The study comprised 682 patients (November 2010 to September 2011) presenting at the emergency department with chest pain and normal hs-cTnT (14 ng/l). The main end point was major adverse cardiac events (MACE: death, myocardial infarction, readmission for unstable angina, or revascularization) at a 4-year median follow-up; secondary end point was 30-day MACE. A …

MalePercentileAcute coronary syndromemedicine.medical_specialtyChest PainClinical Decision-Making030204 cardiovascular system & hematologyChest painSeverity of Illness IndexDiagnosis Differential03 medical and health sciencesElectrocardiography0302 clinical medicineTroponin TInternal medicineSeverity of illnessMedicineHumans030212 general & internal medicineProspective StudiesProspective cohort studyhealth care economics and organizationsbiologymedicine.diagnostic_testbusiness.industryIncidenceEmergency departmentMiddle Agedmedicine.diseasePrognosisTroponinAcute PainSpainbiology.proteinCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessEmergency Service HospitalElectrocardiographyBiomarkersFollow-Up StudiesThe American journal of cardiology
researchProduct

Adult to Adult Living Donor Liver Transplantation in Recipients with Low MELD: A Strategy Intended to Overcome Donor Shortage

2020

Recent series have demonstrated advantages of living donor over deceased donor liver transplantation, with particular benefit for those with low model for end-stage liver disease score. The logic underlying the transplantation of patients before they become too sick is intuitive. It reduces mortality and drop outs from the waiting list and makes transplant surgery less demanding. Those principles have to be balanced with donor safety and transplant benefit for the recipient avoiding early, futile transplantation. The authors report a case of adult to adult right lobe living donor liver transplantation performed for a recipient affected by primary biliary cirrhosis with MELD score of 15, in …

MalePhysiologymedicine.medical_treatmentLiver transplantationSeverity of Illness IndexLiver diseasePostoperative Complications0302 clinical medicinePrimary biliary cirrhosisTransplant surgeryLiving DonorsLiver Transplantation.Liver resectionLiver Cirrhosis BiliaryGastroenterologyCone-Beam Computed TomographyMiddle AgedTreatment Outcomesurgical procedures operativeItalyLiver030220 oncology & carcinogenesisFemaleRisk Adjustment030211 gastroenterology & hepatologyLiving donor liver transplantationHumanAdultmedicine.medical_specialtyTissue and Organ ProcurementClinical Decision-MakingTime-to-TreatmentEnd Stage Liver Disease03 medical and health sciencesInternal medicineSeverity of illnessmedicineHepatectomyHumansIntensive care medicineLiver transplantationbusiness.industryLiving donor liver transplantationHepatologymedicine.diseasePleural EffusionTransplantationSurgeryPostoperative Complicationbusiness
researchProduct

Non-readmission decisions in the intensive care unit under French rules: A nationwide survey of practices.

2018

International audience; Purpose: We investigated, using a multicentre survey of practices in France, the practices of ICU physicians concerning the decision not to readmit to the ICU, in light of current legislation.Materials and methods: Multicentre survey of practices among French ICU physicians via electronic questionnaire in January 2016. Questions related to respondents’ practices regarding re-admission of patients to the ICU and how these decisions were made. Criteria were evaluated by the health care professionals as regards importance for non-readmission.Results: In total, 167 physicians agreed to participate, of whom 165 (99%) actually returned a completed questionnaire from 58 ICU…

MaleQuestionnairesMedical DoctorsHealth Care Providerslcsh:MedicineSocial SciencesNationwide surveyGeographical locationslaw.invention0302 clinical medicineCognitionlawSurveys and QuestionnairesHealth careMedicine and Health SciencesMedicinePsychology030212 general & internal medicineMedical PersonnelPractice Patterns Physicians'lcsh:ScienceMultidisciplinary[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyPalliative CareMiddle AgedTime optimalIntensive care unitHospitals3. Good healthEuropeIntensive Care UnitsProfessionsResearch DesignFemaleFranceResearch ArticleAdultmedicine.medical_specialtyCritical CareClinical Decision-MakingDecision MakingMEDLINELegislationResearch and Analysis MethodsPatient Readmission03 medical and health sciencesGeneral PractitionersPhysiciansHumansFamilyEuropean UnionSurvey Researchbusiness.industrylcsh:RCognitive PsychologyBiology and Life Sciences030208 emergency & critical care medicineHealth CareMulticenter study[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieHealth Care FacilitiesFamily medicinePeople and PlacesCognitive Sciencelcsh:Q[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiePopulation GroupingsPatient ParticipationbusinessHealthcare providers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyNeurosciencePloS one
researchProduct

Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.

2015

Introduction: Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many patients with AF receive chronic anticoagulation, either with vitamin K antagonists (VKAs) or with non-VKA oral anticoagulants (NOACs). We sought to analyze variables associated with prescription of NOAC. Methods: Patients with AF under anticoagulation treatment were prospectively recruited in this observational registry. The sample comprised 1290 patients under chronic anticoagulation for AF, 994 received VKA (77.1%) and 296 NOAC (22.9%). Univariate and multivariate analyses were performed to identify variables associated with use of NOAC. Results: Mean age was 73.8 ± 9.4 years, and 4…

MaleVitamin KClinical Decision-MakingMEDLINEAdministration OralHemorrhage030204 cardiovascular system & hematologyVitamin kanticoagulant treatment03 medical and health sciences0302 clinical medicineClinical decision makingFibrinolytic AgentsAtrial FibrillationmedicineHumansPharmacology (medical)030212 general & internal medicineAgedPharmacologyAged 80 and overbusiness.industrynonvitamin K antagonist oral anticoagulantsAnticoagulantsAtrial fibrillationMiddle Agedmedicine.diseasevitamin K antagonistsIncreased riskAnticoagulant therapyAnesthesiaOral anticoagulantFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose ou…

2018

Summary Non-vitamin K antagonist oral anticoagulants (NOACs) – dabigatran, rivaroxaban, apixaban and edoxaban – are well established in terms of preventing stroke or systemic embolism in patients with non-valvular atrial fibrillation and high thromboembolism risk. When prescribed incorrectly, NOACs are associated with an increased risk of ischaemic events and bleeding. Current NOAC labels explicitly address dose adjustments according to age, body weight, renal function and concomitant treatment with P-glycoprotein inhibitors. The required dose adjustments vary significantly from molecule to molecule, thereby creating a complex dose adjustment environment. Furthermore, recommendations suppor…

Male[SDV]Life Sciences [q-bio]Administration Oral030204 cardiovascular system & hematologychemistry.chemical_compound0302 clinical medicineRisk FactorsEdoxabanAtrial FibrillationDrug Dosage Calculations030212 general & internal medicineStrokeComputingMilieux_MISCELLANEOUSAged 80 and over[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyAtrial fibrillationGeneral MedicineMiddle AgedVitamin K antagonist[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthStroke[SDV] Life Sciences [q-bio]Treatment OutcomeAnesthesiaFemaleApixabanCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtymedicine.drug_classClinical Decision-MakingHemorrhageDabigatran03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicineHumansIntensive care medicineBlood CoagulationAgedHAS-BLEDRivaroxabanDose-Response Relationship Drugbusiness.industryPatient SelectionAnticoagulantsmedicine.diseasechemistrybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Liver transplantation for severe alcoholic hepatitis: A multicenter Italian study

2022

There is increasing evidence that early liver transplantation (eLT), performed within standardized protocols can improve survival in severe alcoholic hepatitis (sAH). The aim of the study was to assess outcomes after eLT for sAH in four Italian LT centers and to compare them with non-responders to medical therapy excluded from eLT. Patients admitted for sAH (2013–2019), according to NIAAA criteria, were included. Patients not responding to medical therapy were placed on the waiting list for eLT after a strict selection. Histological features of explanted livers were evaluated. Posttransplant survival and alcohol relapse were evaluated. Ninety-three patients with severe AH were evaluated (65…

Maleclinical decision-makingTransplantationWaiting Listsalcoholism and substance abuseHepatitis AlcoholicPatient SelectionalllocationSettore MED/09 - MEDICINA INTERNAalcoholism and substance abuse; clinical decision-making; clinical research/practice; liver transplantation/hepatologyalcoholic hepatitiMiddle Agedclinical research/practiceLiver TransplantationRecurrenceMED/18 - CHIRURGIA GENERALEHumansImmunology and AllergyFemaleethicPharmacology (medical)Liver transplantliver transplantation/hepatologyAmerican Journal of Transplantation
researchProduct

Cancer patients’ preferred and perceived level of involvement in treatment decision-making: an epidemiological study

2020

Background: We aimed to analyze preferred and perceived levels of patients’ involvement in treatment decision-making in a representative sample of cancer patients.Material and Methods: We conducted...

Malemedicine.medical_specialtyClinical Decision-MakingMEDLINE030218 nuclear medicine & medical imaging03 medical and health sciencesSex Factors0302 clinical medicineGermanyNeoplasmsSurveys and QuestionnairesEpidemiologymedicineHumansRadiology Nuclear Medicine and imagingAnalysis of VarianceMarital Statusbusiness.industryAge FactorsCancerPatient PreferenceHematologyGeneral MedicineMiddle Agedmedicine.diseaseCross-Sectional StudiesOncology030220 oncology & carcinogenesisFamily medicineEducational StatusFemaleTreatment decision makingPatient ParticipationbusinessDecision Making SharedActa Oncologica
researchProduct